PT  - JOURNAL ARTICLE
AU  - Gupta, Gaurav
AU  - Cpl Emilie, Paquet-Proulx
AU  - Lalonde, Sasha
AU  - Burton, Kira
AU  - LCol Markus, Besemann
AU  - Amir, Minerbi
TI  - Retrospective Analysis of the Utility of Genetic Testing in Predicting Drug Response in Chronic Pain
AID  - 10.1101/2021.04.29.21256336
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.29.21256336
4099  - http://medrxiv.org/content/early/2021/05/04/2021.04.29.21256336.short
4100  - http://medrxiv.org/content/early/2021/05/04/2021.04.29.21256336.full
AB  - Introduction Chronic pain is often unrecognized and/or undertreated, and as a result has significant impact on functional abilities, quality of life, societal participation and health care utilization. Medications remain a mainstay of treatment, but selection for any given patient remains a challenge when trying to predict efficacy and/or side effects. There is interest to see whether genetic analysis of how a given drug is processed for a patient can help with rational drug choices. This appears to have some early support in cardiac, psychiatric and acute pain studies. We studied whether genetic analysis of drug processing using the Pillcheck program could have helped in choosing the appropriate medications in a cohort of patients suffering from chronic pain. To our knowledge this type of study has not been completed in this environment and/or patient population.Methods We retrospectively studied a 31 patient cohort seen in the Canadian Forces Health Services Unit (Ottawa) Physiatry clinic. All patients suffered from a diagnosed chronic pain condition, completed the Pillcheck genetic drug processing analysis and filled-in questionnaires looking at efficacy and side effects of the drugs. We analyzed the correlation between the Pillcheck predictions and participants’ self-reported treatment efficacy and tolerability. The goal was to explore the clinical utility of Pillcheck results in guiding prescriptions for chronic pain patients.Results 31 patients returned completed questionnaires and had samples taken. Forty eight percent of the participants were actively treated with one of the study pain medications, and 84% had been taking at least one of these medications and discontinued. Pillcheck scores did not correlate with self-reported efficacy of any of the medications, nor did it correlate with self-reported side effects. Furthermore, active medications were more likely to receive a score indicating caution should be exerted, than were medications which had been discontinued.Discussion In a small cohort of pain patients with comorbid psychiatric disorders, genetic profiling using Pillcheck did not seem to correlate with reported benefit or side effect profile of commonly prescribed pain medications. Furthermore, discontinued medications were no more likely to be marked as warranting caution than did actively used medications.Conclusion Retrospectively using pharmacogenetics to guide medication selection in Canadian Forces members with chronic pain did not correlate with response or side effects. A larger prospective controlled study, measuring numerous clinical and non- clinical outcomes would be worthwhile in the future before widespread adoption for patients living with chronic pain.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialretrospectiveFunding StatementN/AAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Defence R&D Canada - Toronto HUMAN RESEARCH ETHICS COMMITTEE (HREC) REVIEW All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have all data available https://www.healthaya.com/retrospective-analysis